Changes in Body Mass Index in girls with central precocious puberty after treatment with gonadotropin-releasing hormone agonists
Main Article Content
Abstract
Central precocious puberty (CPP) is a common disorder in girls, and treatment with gonadotropin-releasing hormone (GnRH) agonists may affect body mass index (BMI). This retrospective study of 205 young females with CPP treated with triptorelin at the Vietnam National Children’s Hospital (June 2021 – June 2024) aimed to evaluate changes in BMI and BMI-for-age z-scores (BMIZ) during the first treatment year. The mean age at diagnosis was 7.3 ± 0.9 years old, with 91.7% aged 6 – 8 years old; at baseline, 50.7% were overweight/obese. Mean BMI increased from 17.75 to 18.45 and median BMIZ from 1.09 to 1.34 after 12 months (BMI: p < 0.001; BMIZ: p = 0.002). In the normal-BMI group (n = 91), BMIZ increased linearly from months 3 – 12 (F = 24.319; p < 0.001), with 25% shifting to overweight/obese. In the overweight group (n = 70), BMI remained stable during the first 3 months and then increased significantly from month 6 (F = 16.048; p < 0.001). In the obese/severely obese group (n = 34), BMI decreased slightly at first and then stabilized with minimal change (F = 2.715; p = 0.034). GnRH treatment increases BMI, particularly in children with normal weight; therefore, nutritional monitoring and management are required throughout the treatment period.
Article Details
Keywords
Central precocious puberty, BMI, BMIZ, GnRH agonist, girls
References
2. Zevin EL, Eugster EA. Central precocious puberty: a review of diagnosis, treatment, and outcomes. The Lancet Child & Adolescent Health. 2023; 7(12): 886-896. doi:10.1016/S2352-4642(23)00237-7.
3. Loochi SA, Demol S, Nagelberg N, et al. Gonadotropin releasing hormone analogue therapy in girls with idiopathic precocious puberty/early-fast puberty: dynamics in adiposity indices, eating habits and quality of life. Journal of Pediatric Endocrinology and Metabolism. 2021; 34(3): 373-383. doi:10.1515/jpem-2020-0471.
4. Willemsen RH, Elleri D, Williams RM, et al. Pros and cons of GnRHa treatment for early puberty in girls. Nat Rev Endocrinol. 2014; 10(6): 352-363. doi:10.1038/nrendo.2014.40.
5. Leite AL, Galo E, Antunes A, et al. Do GnRH Agonists Really Increase Body Weight Gain? Evaluation of a Multicentric Portuguese Cohort of Patients With Central Precocious Puberty. Front Pediatr. 2022; 10:816635. doi:10.3389/fped.2022.816635.
6. Hou L, Ying Y, Wu W, et al. The Effect of GnRHa Treatment on Body Mass Index in Central Precocious Puberty: A Systematic Review and Meta-Analysis. Horm Res Paediatr. 2024; 97(5): 419-432. doi:10.1159/000535132.
7. Carel JC, Lahlou N, Roger M, et al. Precocious puberty and statural growth. Hum Reprod Update. 2004; 10(2): 135-147. doi:10.1093/humupd/dmh012.
8. The WHO Child Growth Standards. Accessed September 5, 2025. https://www.who.int/tools/child-growth-standards.
9. Body mass index-for-age (BMI-for-age). Accessed August 7, 2025. https://www.who.int/toolkits/child-growth-standards/standards/body-mass-index-for-age-bmi-for-age.
10. Đồng thuận của Hội Nhi khoa Việt Nam: Hướng dẫn sàng lọc, đánh giá và can thiệp dinh dưỡng cho bệnh nhi. Accessed September 23, 2025. https://tcnhikhoa.vn/index.php/tcnk/article/view/317/297.
11. Liu G, Guo J, Zhang X, et al. Obesity is a risk factor for central precocious puberty: a case-control study. BMC Pediatr. 2021; 21:509. doi:10.1186/s12887-021-02936-1.
12. Shi L, Jiang Z, Zhang L. Childhood obesity and central precocious puberty. Front Endocrinol (Lausanne). 2022; 13:1056871. doi:10.3389/fendo.2022.1056871.
13. Change in body mass index among girls with precocious puberty under treatment. Arch Argent Pediat. Published online April 1, 2016. doi: 10.5546/aap.2016. eng.
14. Kim SW, Kim YB, Lee JE, et al. The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty. Ann Pediatr Endocrinol Metab. 2017; 22(2): 95-101. doi:10.6065/apem.2017.22.2.95.